Clene Inc.

What they do

Clene develops catalytic nanocrystal therapeutics using an electro-crystal-chemistry platform that produces clean-surfaced transition metal nanocrystals. The company's development efforts focus on neurodegenerative diseases with impaired cellular energy metabolism, specifically amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease (PD). Its lead candidate, CNM-Au8, has completed two Phase 2 ALS trials (HEALEY ALS Platform Trial and RESCUE-ALS) and is being prepared for regulatory submission.

Revenue drivers

• Product sales — The company reported product revenue of $90,000 in Q2 2026 and $200,000 for full-year 2025. This is a nominal revenue stream relative to operating expenses.
• Royalty revenue — Royalty revenue is a separate reported line item, though the filings do not disclose a material amount for the most recent periods. This stream is not a significant contributor to total revenue.
• No commercial product — Clene has no approved product generating meaningful commercial revenue. Annual revenue has declined from $723,000 in 2021 to $200,000 in 2025.
• Grant and other income — The company's operations are primarily funded through equity and debt financings rather than revenue, with total assets of $23.0 million and total liabilities of $47.8 million as of June 30, 2026.

Recent performance

For Q2 2026, Clene reported revenue of $90,000, up from $15,000 in Q1 2026. Net cash used in operating activities was $7.1 million for the six months ended June 30, 2026, compared to $9.8 million for the same period in 2025. R&D expenses were $3.5 million for Q2 2026, flat versus Q2 2025. G&A expenses were $1.9 million for Q2 2026. Cash and cash equivalents totaled $9.7 million as of June 30, 2026, compared to $5.2 million as of December 31, 2025.

Strategy

Clene plans to submit an NDA for CNM-Au8 in ALS under the accelerated approval pathway in early Q4 2026. The submission will rely on NfL biomarker data and clinical outcomes from the Phase 2 HEALEY ALS Platform Trial and its open-label extension, the Phase 2 RESCUE-ALS Trial, and the NIH-sponsored Expanded Access Protocol. In May 2026, the company raised $7.0 million in gross proceeds from an underwritten registered direct common stock offering and amended its senior secured convertible debt facilities to extend maturities to August 2027. Management is prioritizing regulatory activities and NDA preparation over near-term commercial expansion.

Risks

• Going concern and financing risk — The company had negative shareholder equity of $24.8 million and $9.7 million in cash as of June 30, 2026, with management stating its resources provide runway only through late Q4 2026.
• Regulatory and clinical risk — The NDA for CNM-Au8 has not yet been submitted, and the FDA's accelerated approval pathway requires demonstrating that NfL change is reasonably likely to predict clinical benefit in ALS, which is not guaranteed.
• Dilution risk — Clene has funded operations through equity issuances, including the January 2026 public offering of Series A and Series B warrants and a May 2026 $7.0 million common stock offering, which have diluted existing shareholders.
• No commercial revenue base — The company has no approved product and annual revenue of $200,000 in 2025, meaning operations depend entirely on external financing and partnership arrangements.

Outlook

Management expects to submit the CNM-Au8 NDA for ALS under the accelerated approval pathway in early Q4 2026 and states that its resources as of June 30, 2026 will provide operating runway through late Q4 2026. The company believes the NfL biomarker and clinical benefit data generated since its last FDA meeting will be critical for a successful review. No guidance on revenue or profitability was provided.